A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway

Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily that plays a key role in the regulation of differentiation, activation and survival of osteoclasts and also in tumor cell migration and bone metastasis. Osteoclast activation induced by RANKL regulates hematopoietic stem cell mobilization as part of homeostasis and host defense mechanisms thereby linking regulation of hematopoiesis with bone remodeling. Binding of RANKL to its receptor, Receptor activator of nuclear factor-kappa B (RANK) activates molecules such as NF-kappa B, mitogen activated protein kinase (MAPK), nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). Although the molecular and cellular roles of these molecules have been reported previously, a systematic cataloging of the molecular events induced by RANKL/RANK interaction has not been attempted. Here, we present a comprehensive reaction map of the RANKL/RANK-signaling pathway based on an extensive manual curation of the published literature. We hope that the curated RANKL/RANK-signaling pathway model would enable new biomedical discoveries, which can provide novel insights into disease processes and development of novel therapeutic interventions. Database URL: http://www.netpath.org/pathways?path_id=NetPath_21

[1]  Gary D Bader,et al.  BioPAX – A community standard for pathway data sharing , 2010, Nature Biotechnology.

[2]  R. Owens,et al.  Structural and Functional Insights of RANKL–RANK Interaction and Signaling , 2010, The Journal of Immunology.

[3]  Ugur Dogrusoz,et al.  VISIBIOweb: visualization and layout services for BioPAX pathway models , 2010, Nucleic Acids Res..

[4]  Chris Sander,et al.  ChiBE: interactive visualization and manipulation of BioPAX pathway models , 2010, Bioinform..

[5]  Sandra E. Orchard,et al.  Molecular Interactions and Data Standardisation , 2010, Proteome Bioinformatics.

[6]  Gary D Bader,et al.  NetPath: a public resource of curated signal transduction pathways , 2010, Genome Biology.

[7]  Y. Abu-Amer,et al.  Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis , 2009, Journal of cellular biochemistry.

[8]  A. Haeseler,et al.  Central control of fever and female body temperature by RANKL/RANK , 2009, Nature.

[9]  Kumaran Kandasamy,et al.  PathBuilder - open source software for annotating and developing pathway resources , 2009, Bioinform..

[10]  R. Cole,et al.  Identification of c‐Src tyrosine kinase substrates in platelet‐derived growth factor receptor signaling , 2009, Molecular oncology.

[11]  Chris T. Evelo,et al.  Community curation on WikiPathways: How we assist knowledge collection , 2009 .

[12]  J. Pelletier,et al.  New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? , 2009, The Keio journal of medicine.

[13]  M. J. Marshall,et al.  RANK, RANKL and osteoprotegerin in bone biology and disease , 2009, Current reviews in musculoskeletal medicine.

[14]  O. Dittrich‐Breiholz,et al.  A comprehensive map of the IL-1R signalling network , 2009, Cell Communication and Signaling.

[15]  R. Faccio,et al.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo , 2009, Proceedings of the National Academy of Sciences.

[16]  E. Montgomery,et al.  Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers , 2009, Cancer biology & therapy.

[17]  Chris Mungall,et al.  AmiGO: online access to ontology and annotation data , 2008, Bioinform..

[18]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[19]  S. Teitelbaum,et al.  Tumor Necrosis Factor Receptor-associated Factor 6 Is an Intranuclear Transcriptional Coactivator in Osteoclasts* , 2008, Journal of Biological Chemistry.

[20]  R. Faccio,et al.  RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. , 2008, The Journal of clinical investigation.

[21]  T. Yoneda,et al.  JNK/c‐Jun Signaling Mediates an Anti‐Apoptotic Effect of RANKL in Osteoclasts , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  Shao-Cong Sun,et al.  Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. , 2008, The Journal of clinical investigation.

[23]  W. Zou,et al.  RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation , 2008, Proceedings of the National Academy of Sciences.

[24]  W. Alexander,et al.  A Novel Mutation in the Nfkb2 Gene Generates an NF-κB2 “Super Repressor”1 , 2007, The Journal of Immunology.

[25]  N. Bishop,et al.  Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL , 2007, Nature Genetics.

[26]  E. Wagner,et al.  NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1* , 2007, Journal of Biological Chemistry.

[27]  J. Penninger,et al.  RANK signals from CD4+3− inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla , 2007, The Journal of Experimental Medicine.

[28]  W. Alexander,et al.  A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor". , 2007, Journal of immunology.

[29]  Alexander R. Pico,et al.  GenMAPP 2: new features and resources for pathway analysis , 2007, BMC Bioinformatics.

[30]  Ron Bose,et al.  Phosphoproteomic analysis of Her2/neu signaling and inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Kitano,et al.  A comprehensive map of the toll-like receptor signaling network , 2006, Molecular systems biology.

[32]  J. Penninger,et al.  Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2 , 2006, Molecular and Cellular Biology.

[33]  Y. Kadono,et al.  Identification of an Alternatively Spliced Variant of Ca2+-promoted Ras Inactivator as a Possible Regulator of RANKL Shedding* , 2005, Journal of Biological Chemistry.

[34]  Osami Kanagawa,et al.  NF-κB–inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis , 2005 .

[35]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[36]  Georg Schett,et al.  IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss , 2005, The Journal of experimental medicine.

[37]  H. Kitaura,et al.  NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. , 2005, The Journal of clinical investigation.

[38]  S. Akira,et al.  Osteoclast Differentiation Is Impaired in the Absence of Inhibitor of κB Kinase α* , 2004, Journal of Biological Chemistry.

[39]  C. Sander,et al.  The HUPO PSI's Molecular Interaction format—a community standard for the representation of protein interaction data , 2004, Nature Biotechnology.

[40]  S. Akira,et al.  Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. , 2004, The Journal of biological chemistry.

[41]  Sakae Tanaka,et al.  Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. , 2004, The Journal of clinical investigation.

[42]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.

[43]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[44]  W. Lindenmaier,et al.  Enhanced Effector and Memory CTL Responses Generated by Incorporation of Receptor Activator of NF-κB (RANK)/RANK Ligand Costimulatory Molecules into Dendritic Cell Immunogens Expressing a Human Tumor-Specific Antigen 12 , 2003, The Journal of Immunology.

[45]  C. Blobel,et al.  Catalytic Properties of ADAM19* , 2003, Journal of Biological Chemistry.

[46]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[47]  M. Ostrowski,et al.  Cooperation of TNF Family Members CD40 Ligand, Receptor Activator of NF-κB Ligand, and TNF-α in the Activation of Dendritic Cells and the Expansion of Viral Specific CD8+ T Cell Memory Responses in HIV-1-Infected and HIV-1-Uninfected Individuals 1 , 2003, The Journal of Immunology.

[48]  E. Wagner,et al.  JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.

[49]  D. Adams,et al.  Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. , 2002, Blood.

[50]  S. Kumta,et al.  Sensitivity to Quorn mycoprotein (Fusarium venenatum) in a mould allergic patient , 2002, Journal of Clinical Pathology.

[51]  R. Kitazawa,et al.  RANK ligand is a prerequisite for cancer‐associated osteolytic lesions , 2002, The Journal of pathology.

[52]  Y. Kadono,et al.  Possible Involvement of IκB Kinase 2 and MKK7 in Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor κB Ligand , 2002 .

[53]  Tadashi Hata,et al.  Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-Å Resolution* , 2002, The Journal of Biological Chemistry.

[54]  N. Sakurai,et al.  Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. , 2002, Molecular and cellular biology.

[55]  Y. Kadono,et al.  Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. , 2002, Journal of Bone and Mineral Research.

[56]  R. Bataille,et al.  Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. , 2001, Blood.

[57]  C. Nelson,et al.  Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. , 2001, The Journal of clinical investigation.

[58]  M. Naramura,et al.  A Positive Regulatory Role for Cbl Family Proteins in Tumor Necrosis Factor-related Activation-induced Cytokine (TRANCE) and CD40L-mediated Akt Activation* , 2001, The Journal of Biological Chemistry.

[59]  William Maloney,et al.  Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.

[60]  L. Lum,et al.  Biochemical and Pharmacological Criteria Define Two Shedding Activities for TRANCE/OPGL That Are Distinct from the Tumor Necrosis Factor α Convertase* , 2001, The Journal of Biological Chemistry.

[61]  L. Hofbauer,et al.  Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.

[62]  L. Lum,et al.  Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. , 2001, The Journal of biological chemistry.

[63]  M. Tsujimoto,et al.  Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)* , 2000, The Journal of Biological Chemistry.

[64]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[65]  E. Wagner,et al.  Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. , 2000, Bone.

[66]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[67]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[68]  L. Lum,et al.  Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.

[69]  L. Lum,et al.  Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.

[70]  Yongwon Choi,et al.  TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts , 1998, The Journal of experimental medicine.

[71]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[72]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[73]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[74]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[75]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[76]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[77]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[78]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.